Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study to Assess the Efficacy and Safety of SPY002-072 in Adults With Moderately to Severely Active Rheumatologic Disease

NCT07148414 is registered in ClinicalTrials.gov with Spyre Therapeutics, Inc. as lead sponsor.

NCT NCT07148414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07148414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study to Assess the Efficacy and Safety of SPY002-072 in Adults With Moderately to Severely Active Rheumatologic Disease
Lead sponsor
Spyre Therapeutics, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 21, 2025
Completion date
March 31, 2028
Enrollment
285 (estimated)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

axial spondyloarthritis, axspa, psa (psoriatic arthritis), psoriatic arthritis, rheumatic diseases, rheumatic joint disease, rheumatoid arthritis, rheumatologic disease